|
Movement Disorders
Citations 211-220 of 455 total displayed.
|
Past content
(since Jan 1998):
|
- Original Contributions
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
- M. Leann Dodd; Kevin J. Klos; James H. Bower; Yonas E. Geda; Keith A. Josephs; J. Eric Ahlskog
Arch Neurol 2005; 62: 1377-1381.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging: Probable Manganese Neurotoxicity
- Kevin J. Klos; J. Eric Ahlskog; Keith A. Josephs; Robert D. Fealey; Clayton T. Cowl; Neeraj Kumar
Arch Neurol 2005; 62: 1385-1390.
[Abstract]
[Full text]
[PDF]
- Correspondence
Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease—Reply
- Ruediger Hilker; Karl Herholz; Wolf-Dieter Heiss
Arch Neurol 2005; 62: 1480-a-1481-a.
[Extract]
[Full text]
[PDF]
- Correspondence
Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease
- Per Borghammer; Yoshitaka Kumakura; Paul Cumming
Arch Neurol 2005; 62: 1480.
[Extract]
[Full text]
[PDF]
- Original Contributions
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
- Jerry Avorn; Sebastian Schneeweiss; Lewis R. Sudarsky; Joshua Benner; Yuka Kiyota; Raisa Levin; Robert J. Glynn
Arch Neurol 2005; 62: 1242-1248.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Management of Referred Deep Brain Stimulation Failures: A Retrospective Analysis From 2 Movement Disorders Centers
- Michael S. Okun; Michele Tagliati; Michael Pourfar; Hubert H. Fernandez; Ramon L. Rodriguez; Ron L. Alterman; Kelly D. Foote
Arch Neurol 2005; 62: 1250-1255.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Prognosis of Parkinson Disease: Risk of Dementia and Mortality: The Rotterdam Study
- Lonneke M. L. de Lau; C. Maarten A. Schipper; Albert Hofman; Peter J. Koudstaal; Monique M. B. Breteler
Arch Neurol 2005; 62: 1265-1269.
[Abstract]
[Full text]
[PDF]
- Observations
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
- Ron Tintner; Prasad Manian; Polly Gauthier; Joseph Jankovic
Arch Neurol 2005; 62: 1290-1295.
[Abstract]
[Full text]
[PDF]
- Correspondence
Reexamination of the TEMPO Study
- Clifford W. Shults
Arch Neurol 2005; 62: 1320.
[Extract]
[Full text]
[PDF]
- Correspondence
Reexamination of the TEMPO Study—Reply
- Andrew Siderowf; Shirley Eberly; David Oakes; Ira Shoulson; for the Parkinson Study Group TEMPO Steering Committee
Arch Neurol 2005; 62: 1321-a.
[Extract]
[Full text]
[PDF]
|
|
